Alteogen, Inc.   Report issue

For profit Phase 1
Founded: Daejeon Korea, Republic of (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2016
NCT03242239
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alteogen, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Macular Degeneration (Phase 1)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 5